Moderna will today submit its Covid vaccine for emergency approval in the US and Europe, after the final analysis of its last-stage trial showed that the jab is 94.1 per cent effective at preventing infection. Results from the Massachusetts-based company’s stage three trials mark a landmark success for the vaccine, with the firm’s chief executive Stephane Bancel claiming it could ‘change the course of this pandemic’. Only 11 volunteers who received the jab tested positive for the coronavirus. For comparison, there were 185 cases in the equally-sized placebo group. More than 30,000 participants have taken part in the study since it began several months ago. Moderna claimed the vaccine’s efficacy against preventing severe Covid-19 was 100 per cent, with none of the 30 patients deemed to be critically-ill getting the jab, which needs to be taken in two shots. The firm also said there were no safety concerns with the jab, and that the vaccine worked in all age groups. Experts today heralded the results as ‘very good news’. Britain has already bought 7million doses of Moderna’s vaccine, with officials left scrambling to secure the jab when promising preliminary results came out a fortnight ago. Matt Hancock has already admitted…